Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 trial of zerlasiran

Next Previous
Search
Trial Profile

Phase 3 trial of zerlasiran

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 18 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zerlasiran (Primary)
  • Indications Cardiovascular disorders
  • Focus Therapeutic Use

    • Most Recent Events

    • 27 Feb 2025 According to a Silence Therapeutics media release, the company will only initiate the Phase 3 cardiovascular outcomes study once a partner is secured. The decision not to initiate the zerlasiran Phase 3 outcomes study without a partner extends projected cash runway into 2027. The company has Progressed core activities to ensure the zerlasiran program is Phase 3 ready in the first half of 2025.
    • 27 Feb 2025 According to a Silence Therapeutics media release, the company received positive regulatory feedback from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan on the Phase 3 cardiovascular (CV) outcomes study design for zerlasiran in patients with elevated lipoprotein(a) (Lp(a)) and at high risk of a CV event.
    • 21 Jun 2024 According to a Silence Therapeutics media release, the company look forward to advancing zerlasiran to phase 3 as a potential treatment for this major unmet need in cardiovascular disease.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top